Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CBLB | Q13191 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12512974 | 1.00 | MAPK1 (0.44) | MAPK1ALDH1A1CBLBCYP1A2CYP2C19 | |
| SCHEMBL31030362 | 0.80 | MAPK1 (0.49) | MAPK1ALDH1A1CBLBCYP1A2CYP2C19 | |
| SCHEMBL18806993 | 0.80 | MAPK1 (0.49) | MAPK1ALDH1A1CBLBCYP1A2CYP2C19 | |
| SCHEMBL8141395 | 0.80 | MAPK1 (0.44) | MAPK1ALDH1A1CBLBCYP1A2CYP2C19 | |
| SCHEMBL21587664 | 0.78 | MAPK1 (0.46) | MAPK1ALDH1A1CBLBCYP1A2CYP2C19 | |
| SCHEMBL22516955 | 0.73 | MAPK1 (0.46) | MAPK1ALDH1A1CBLBCYP1A2CYP2C19 | |
| SCHEMBL16548434 | 0.72 | MAPK1 (0.53) | MAPK1ALDH1A1CYP1A2CYP2C19ELOVL1 | |
| SCHEMBL257500 | 0.72 | — | — | |
| SCHEMBL8511546 | 0.71 | MAPK1 (0.47) | MAPK1ALDH1A1CBLBCYP1A2CYP2C19 | |
| SCHEMBL22143639 | 0.71 | MAPK1 (0.56) | MAPK1ALDH1A1CYP1A2CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178092-A1 | HIV-1 Protease Inhibitors | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178092-A1 | HIV-1 Protease Inhibitors | SERPINB1, PRSS1, TMPRSS4 | MAPK1 3160/4885ALDH1A1 2716/4885CBLB 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.